In their study, out of the 42 HGSC patients, 27 (64%) had at least one detectable somatic mutation in their plasma ctDNA (range: 1–3 mutations/sample), and approximately 50% of the ovarian cancer patients had TP53 mutations. The gene discussed is TP53; the disease is ovarian cancer.